GATA3 wild type MCF-7 breast cancer cells GATA3 D336fs*17 mutant CAMA1 breast cancer cells

Case ID:
C14892
Unmet Need
Mutations in the transcription factor-encoding gene GATA3 are highly prevalent in breast cancer but the functional role of mutant GATA3 in malignancy remains unclear due in part to the absence of appropriate research tools. Human breast cancer cell lines with mutant and wild-type GATA3, including MCF-7 and CAMA1, respectively, are commercially available. MCF-7 harbors a GATA3 frame shift mutation (D336Gfs*17) commonly observed in breast cancer, but in order to determine the precise role of this mutation, an isogenic cell line with wild-type GATA3 is required. Alternatively, a cell line isogenic to CAMA1, but with mutant GATA3 would also be an appropriate mutant/control pairing that could be used to probe the function of this specific GATA3 mutation in breast cancer.
 
Technology Overview
Johns Hopkins researchers used recombinant adeno-associated viral (rAAV) vectors to generate two different cell lines useful for human breast cancer research related to GATA3 mutation. The first is derived from MCF-7 cells in which mutant GATA3 was replaced with the wild-type gene for all alleles. The second is derived from CAMA-1 cells in which the GATA3 D336Gfs*17 mutation was introduced into one allele.
 
Stage of Development
Both of these cell lines have been validated, and initial experiments have been performed to characterize the functional effects of GATA3 manipulation in vitro and in vivo as well as in preclinical drug studies, demonstrating the utility of these cell lines as basic research and translational tools.
 
Publications
PLoS Genet. 2016 Sep 2;12(9):e1006279.
 
Patent Information:
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Christine Joseph
cjoseph6@jhmi.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum